1 week Ago By Defense World Staff
Anavex Life Sciences Corp. ( NASDAQ:AVXL – Get Free Report ) saw a significant increase in short interest in December. As of December 15th, there was short interest totalling 20,820,000 shares, an increase of 5.
7% from the November 30th total of 19,690,000 shares. Based on an average daily trading volume, of 1,320,000 shares, the short-interest ratio is currently 15.8 days.
Analyst Upgrades and Downgrades A number of equities analysts recently issued reports on AVXL shares. HC Wainwright increased their price target on shares of Anavex Life Sciences from $40.00 to $42.
00 and gave the stock a “buy” rating in a research note on Thursday, December 26th. D. Boral Capital reissued a “buy” rating and issued a $46.
00 price target on shares of Anavex Life Sciences in a research note on Monday, December 23rd. View Our Latest Research Report on Anavex Life Sciences Anavex Life Sciences Stock Performance Anavex Life Sciences ( NASDAQ:AVXL – Get Free Report ) last announced its quarterly earnings data on Monday, December 23rd. The biotechnology company reported ($0.
14) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.03.
Equities research analysts predict that Anavex Life Sciences will post -0.55 EPS for the current year. Institutional Investors Weigh In On Anavex Life Sciences Hedge funds and other institutional investors have recently bought and sold shares of the business.
Orion Capital Management LLC grew its holdings in shares of Anavex Life Sciences by 666.7% during the third quarter. Orion Capital Management LLC now owns 11,500 shares of the biotechnology company’s stock valued at $65,000 after buying an additional 10,000 shares during the last quarter.
PVG Asset Management Corp purchased a new stake in shares of Anavex Life Sciences during the third quarter valued at approximately $74,000. Atria Investments Inc purchased a new stake in shares of Anavex Life Sciences during the third quarter valued at approximately $76,000. BNP Paribas Financial Markets grew its holdings in shares of Anavex Life Sciences by 97.
0% during the third quarter. BNP Paribas Financial Markets now owns 15,074 shares of the biotechnology company’s stock valued at $86,000 after buying an additional 7,421 shares during the last quarter. Finally, China Universal Asset Management Co.
Ltd. grew its holdings in shares of Anavex Life Sciences by 64.0% during the third quarter.
China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 6,366 shares during the last quarter.
Hedge funds and other institutional investors own 31.55% of the company’s stock. About Anavex Life Sciences ( Get Free Report ) Anavex Life Sciences Corp.
, a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. Recommended Stories Five stocks we like better than Anavex Life Sciences The How And Why of Investing in Oil Stocks Work and Play: Investing in the Rise of Bleisure Travel What Are Dividend Contenders? Investing in Dividend Contenders Top Dividend Stocks to Buy Now as Bond Yields Could Lower High Dividend REITs: Are They an Ideal Way to Diversify? SAP: AI Tailwinds Accelerating Enterprise Cloud Business Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
